Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03180996
Other study ID # FACT-001
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date September 11, 2017
Est. completion date December 31, 2030

Study information

Verified date June 2023
Source Vascutek Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is a prospective non-interventional, multi-centre study of the Vascutek Fenestrated Anaconda™ system, and is essentially a post-market study. The Vascutek Fenestrated Anaconda™ system is a custom made device used for the treatment of Abdominal Aortic Aneurysm.


Description:

Abdominal Aortic Aneurysm (AAA) is a life threatening disease. Endovascular repair of infrarenal abdominal aortic aneurysms (EVAR) has replaced open surgical repair as the standard of care treatment for most patients. Endovascular repair offers several benefits over open surgical repair, including: less invasive procedure, faster recovery, lower morbidity and lower early post-operative mortality. The configuration of vascular anatomy is important to the successful placement and subsequent performance of infrarenal EVAR devices. In particular aortic neck angulation and length are important for the success of EVAR. Challenging necks with an aortic diameter ≥28 mm, angulation ≥60°, length <10mm, circumferential thrombus, reversed tapered configuration or neck with bulging, make it more difficult to oppose the endograft to the aortic wall and are related to an increased risk of type Ia endoleak and reinterventions. In order to overcome these issues, fenestrated and branched stent grafts have been developed. Fenestrated and branched endovascular aneurysm repair is now a routinely utilised procedure in the treatment of complex aortic aneurysm anatomy, especially in patients unsuitable for open surgical repair. The Fenestrated Anaconda™ device (Vascutek Ltd, Glasgow, Scotland, UK) has been commercially available since 2010. The Fenestrated Anaconda™ device has potential advantages over other FEVAR devices, since it can be repositioned after deployment, has a magnet-assisted limb cannulation, and the device contains less metal, allowing a better view of the radiological markers on the device during intra-operative imaging. Additionally, the potential to position fenestrations anywhere in the main body is unrestricted due to the absence of other stent structures. This prospective, real world study of the Fenestrated Anaconda™ device will provide insight into both the short and long term clinical outcomes of the device. An attempt will be made to identify predictors of success or failure, and this study will help to identify patients that are likely to benefit from repair and improve results. The effect of FEVAR on post-operative patient reported quality of life will be assessed. In addition, the study will provide insight into the potential decline in renal function after FEVAR, a well-known concern after both EVAR and FEVAR.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 160
Est. completion date December 31, 2030
Est. primary completion date March 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients must meet all of the criteria below in order to be eligible for inclusion in the study - 1. Patient is aged 18 years or over on the date of consent 2. Patient is willing and able to comply with all study procedures and study follow-up visits 3. Patient is willing and able to give written informed consent to participate in study 4. Patient has a juxtrarenal or suprarenal abdominal aortic aneurysm (AAA) with maximum sac diameter = 5.5cm, or an AAA = 4.5 cm which has increased by > 1.0 cm in the past year 5. Patient is anatomically suitable for a bifurcated Fenestrated Anaconda™ device NOTE: Both the treating Investigator and the Manufacturer must agree that the proposed patient's anatomy is suitable for treatment using the Fenestrated Anaconda™ device. Where the Investigator proposes that the patient anatomy is suitable and the Manufacturer subsequently disagrees, the patient will be recorded as a screen failure and deemed not eligible for the study. Exclusion Criteria: Any patient who meets any of the criteria below will be excluded from participation in the study - 1. Patient has a life expectancy < 2 years, as judged by the Investigator 2. Patient has psychiatric or other condition that in the opinion of the Investigator may limit their ability to comply with study procedures 3. Patient is participating in another clinical study which in the opinion of the Investigator could influence the outcomes of this study 4. Patient has a known allergy to any device component (polyester, nitinol, nickel) 5. Patient has a coagulopathy or uncontrolled bleeding disorder 6. Patient has a ruptured, leaking or mycotic aneurysm 7. Patient has a serum creatinine (S-Cr) level > 2.0 mg/dL (177 µmol/L) 8. Patient has had CVA or MI within three months of enrolment or treatment 9. Patient has a connective tissue disease (e.g. Marfan Syndrome) 10. Patient has had a previously inserted endovascular stent in the abdominal aorta 11. Patient is pregnant (female of childbearing potential only)

Study Design


Intervention

Device:
Vascutek Fenestrated Anaconda™ Custom AAA Stent Graft System
Fenestrated Endovascular Aortic Repair (FEVAR)

Locations

Country Name City State
Australia Epworth Richmond Private Hospital Melbourne Victoria
Australia Hollywood Medical Centre Perth Western Australia
Austria Wilhelminenspital Vienna
Canada Peter Lougheed Centre Calgary Alberta
Netherlands Rijnstate Hospital Arnhem
Netherlands Medisch Spectrum Twente (MST) Enschede
Netherlands Universitair Medisch Centrum Groningen (UMCG) Groningen
Netherlands Antonius Ziekenhuis Nieuwegein
United Kingdom Frimley Park Hospital Camberley
United Kingdom Imperial College, St Mary's Hospital London
United Kingdom Freeman Hospital Newcastle upon Tyne Tyne And Wear

Sponsors (1)

Lead Sponsor Collaborator
Vascutek Ltd.

Countries where clinical trial is conducted

Australia,  Austria,  Canada,  Netherlands,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients who experience Treatment Success. Treatment success is defined as freedom from the following: Type I and III endoleak; stent graft migration; AAA enlargement; AAA rupture; conversion to open surgery; non-patent endoluminal grafts and/or significant twists, kinks or obstruction; aneurysm-related patient death. 1 year post-procedure
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04227054 - Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks N/A
Active, not recruiting NCT03687489 - Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System N/A
Active, not recruiting NCT03507413 - Metformin Therapy in Non-diabetic AAA Patients Phase 2/Phase 3
Not yet recruiting NCT05756283 - The PREHAAAB Trial: Multimodal Prehabilitation for Patients Awaiting Open Abdominal Aortic Aneurysm Repair N/A
Not yet recruiting NCT04089241 - Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair N/A
Active, not recruiting NCT02604303 - A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms
Terminated NCT02469376 - Evaluation of a New Imagingtechnologie for Thrombosis Phase 1
Completed NCT02224794 - LIFE Study: Least Invasive Fast-Track EVAR
Completed NCT02229006 - Sodium Fluoride Imaging of Abdominal Aortic Aneurysms N/A
Terminated NCT01843335 - Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair N/A
Completed NCT01118520 - AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) Phase 2
Terminated NCT01425242 - Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension N/A
Completed NCT00746122 - Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair N/A
Completed NCT03952780 - Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)
Completed NCT00583414 - Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients N/A
Recruiting NCT05864560 - Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up
Completed NCT01683084 - Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms Phase 4
Completed NCT02493296 - The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study
Completed NCT03320408 - Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers
Completed NCT03837704 - Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking. N/A